Can Platelet-Rich plasma boost microneedling for skin amyloidosis?
NCT ID NCT07360860
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding platelet-rich plasma (PRP) to microneedling improves itching and dark patches in macular amyloidosis better than microneedling alone. Thirty adults with the condition will have each side of their face treated differently, and results will be checked with photos, skin microscopy, and patient satisfaction surveys. The goal is to see if the combination offers a safe, more effective option for this stubborn skin condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Platelet-rich plasma (PRP)
What this could lead to
If it works, this could offer a more effective way to reduce itching and skin darkening in people with macular amyloidosis.
What could go wrong
This is a very small, early study with only 30 people, so results may not apply to everyone. The improvement may be modest or no better than microneedling alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MACULAR AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••